Related Experiment Video
Updated: May 18, 2026
Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
Published on: April 2, 2017
RNA interference targeting RelB attenuates liver ischemia/reperfusion injury
1Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, Regenerative Research Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Background:
RNA interference targeting RelB can significantly attenuate ischemia/reperfusion (I/R)-induced renal dysfunction, but its roles in liver I/R injury remain to be defined. We have investigated whether siRNA targeting of RelB in liver could also elicit protection against I/R injury.
Materials And Methods:
A RelB miRNA RNAi expression plasmid, a scrambled plasmid, or phosphate-buffered saline (50 μg of the plasmid diluted in phosphate-buffered saline, 8% wt/vol) were rapidly injected, within 6-8 s, into mouse tail veins 24 h before liver I/R. Mice were subjected to 30 min of 70% hepatic ischemia or to a sham operation. Six h after reperfusion, blood and liver tissue samples were collected for subsequent assays.
Results:
The expression level of RelB was reduced in the RelB RNAi group compared with the control group, while it was increased in the I/R group. In the sham group, malondialdehyde, myeloperoxidase (MPO), and superoxide dismutase serum levels were almost the same, but the alanine aminotransferase level in the untreated group was 20- to 25-fold lower than in the other groups. In I/R-treated mice, although alanine aminotransferase, malondialdehyde, and MPO serum levels in the RelB RNAi group were lower than in other groups, all were higher than in the sham group. Silencing RelB could inhibit the decrease of superoxide dismutase activity and the upregulation of MPO and tumor necrosis factor α induced by I/R injury.
Conclusions:
Silencing RelB can protect the liver against I/R-induced damage. Therefore, it is a promising therapeutic target for protection against I/R injury in the liver.
Insights
Silencing RelB protects the liver from ischemia/reperfusion (I/R) injury. This study shows targeting RelB with siRNA reduces liver damage markers and inflammation, indicating its therapeutic potential.
Area of Science:
- Hepatology
- Molecular Biology
- Immunology
Background:
- Ischemia/reperfusion (I/R) injury significantly impacts liver function.
- RNA interference (RNAi) targeting RelB shows promise in renal I/R injury.
- The role of RelB in liver I/R injury requires further investigation.
Purpose of the Study:
- To investigate the protective effects of RelB-targeting siRNA against liver I/R injury.
- To determine if silencing RelB can mitigate I/R-induced liver damage.
Main Methods:
- Mice received RelB miRNA RNAi expression plasmid via tail vein injection 24 hours before liver I/R.
- Mice underwent 30 minutes of hepatic ischemia followed by 6 hours of reperfusion.
- Liver tissue and blood samples were collected for biochemical and molecular analyses.
Main Results:
- RelB expression was reduced in the RelB RNAi group compared to controls.
- Silencing RelB decreased serum levels of alanine aminotransferase, malondialdehyde, and myeloperoxidase (MPO) post-I/R.
- RelB silencing inhibited I/R-induced decrease in superoxide dismutase activity and upregulation of MPO and tumor necrosis factor α.
Conclusions:
- Silencing RelB offers significant protection against liver ischemia/reperfusion injury.
- RelB represents a potential therapeutic target for mitigating liver I/R damage.
